Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1985 1
1990 1
1992 1
1997 1
1998 1
2002 2
2005 1
2007 1
2012 1
2013 2
2016 2
2017 4
2018 4
2019 7
2020 2
2021 6
2022 7
2023 6
2024 3

Text availability

Article attribute

Article type

Publication date

Search Results

46 results

Results by year

Filters applied: . Clear all
Page 1
New developments in diagnosis, prognostication, and treatment of advanced systemic mastocytosis.
Reiter A, George TI, Gotlib J. Reiter A, et al. Blood. 2020 Apr 16;135(16):1365-1376. doi: 10.1182/blood.2019000932. Blood. 2020. PMID: 32106312 Free article. Review.
Sensitive detection of the recurrent KIT D816V mutation and use of next-generation sequencing (NGS) panels to profile the genetic landscape of SM variants have been critical adjuncts to the diagnosis and subclassification of SM, and development of clinical-molecular progno …
Sensitive detection of the recurrent KIT D816V mutation and use of next-generation sequencing (NGS) panels to profile the genetic landscape …
Safety and efficacy of avapritinib in advanced systemic mastocytosis: the phase 1 EXPLORER trial.
DeAngelo DJ, Radia DH, George TI, Robinson WA, Quiery AT, Drummond MW, Bose P, Hexner EO, Winton EF, Horny HP, Tugnait M, Schmidt-Kittler O, Evans EK, Lin HM, Mar BG, Verstovsek S, Deininger MW, Gotlib J. DeAngelo DJ, et al. Nat Med. 2021 Dec;27(12):2183-2191. doi: 10.1038/s41591-021-01538-9. Epub 2021 Dec 6. Nat Med. 2021. PMID: 34873347 Free PMC article. Clinical Trial.
Advanced systemic mastocytosis (AdvSM) is a rare hematologic neoplasm driven by the KIT D816V mutation and associated with poor survival. ...
Advanced systemic mastocytosis (AdvSM) is a rare hematologic neoplasm driven by the KIT D816V mutation and associated with poo …
Blinatumomab in Practice.
Lantz J, Pham N, Jones C, Reed D, El Chaer F, Keng M. Lantz J, et al. Curr Hematol Malig Rep. 2024 Feb;19(1):1-8. doi: 10.1007/s11899-023-00714-7. Epub 2023 Dec 7. Curr Hematol Malig Rep. 2024. PMID: 38060085 Review.
PURPOSE OF REVIEW: Acute lymphoblastic leukemia (ALL) is a rare hematologic neoplasm in adults, with most cases defined by pathology related to abnormal B cell proliferation known as B-cell ALL. ...
PURPOSE OF REVIEW: Acute lymphoblastic leukemia (ALL) is a rare hematologic neoplasm in adults, with most cases defined by pat …
Avapritinib for advanced systemic mastocytosis.
Gotlib J, Reiter A, DeAngelo DJ. Gotlib J, et al. Blood. 2022 Oct 13;140(15):1667-1673. doi: 10.1182/blood.2021014612. Blood. 2022. PMID: 35877999 Free article.
The phase 1 EXPLORER and phase 2 PATHFINDER trials demonstrated that avapritinib can elicit complete and durable clinical responses and molecular remission of KIT D816V. Key management challenges relate to the complex mutational landscape of AdvSM, often found with an asso …
The phase 1 EXPLORER and phase 2 PATHFINDER trials demonstrated that avapritinib can elicit complete and durable clinical responses a …
Avapritinib for Systemic Mastocytosis.
Bose P, Verstovsek S. Bose P, et al. Expert Rev Hematol. 2021 Aug;14(8):687-696. doi: 10.1080/17474086.2021.1959315. Epub 2021 Aug 6. Expert Rev Hematol. 2021. PMID: 34289787
The vast majority of cases are indolent, with near-normal life expectancy, although symptoms can be severe. AdvSM, comprising aggressive SM, SM with an associated hematologic neoplasm and mast cell leukemia, however, carries a poor prognosis. ...
The vast majority of cases are indolent, with near-normal life expectancy, although symptoms can be severe. AdvSM, comprising aggressive SM, …
Recent advance of small-molecule drugs for clinical treatment of multiple myeloma.
Zhao JH, Xu QL, Ma S, Li CY, Zhang HC, Zhao LJ, Zhang ZY. Zhao JH, et al. Eur J Med Chem. 2023 Sep 5;257:115492. doi: 10.1016/j.ejmech.2023.115492. Epub 2023 May 16. Eur J Med Chem. 2023. PMID: 37210838 Review.
Multiple myeloma (MM) is a hematologic neoplasm of plasma cells that is currently deemed incurable. ...As basic research continues to advance, novel therapeutic agents, including panobinostat, a histone deacetylase inhibitor, and selinexor, a nuclear export inhibito …
Multiple myeloma (MM) is a hematologic neoplasm of plasma cells that is currently deemed incurable. ...As basic research conti …
Clonal hematopoiesis in hematopoietic stem cell transplantation.
Wilk CM, Manz MG, Boettcher S. Wilk CM, et al. Curr Opin Hematol. 2021 Mar 1;28(2):94-100. doi: 10.1097/MOH.0000000000000631. Curr Opin Hematol. 2021. PMID: 33394723 Review.
PURPOSE OF REVIEW: Clonal hematopoiesis (CH) is characterized by the acquisition of somatic mutations and subsequent expansion of mutated hematopoietic stem and progenitor cell (HSPC) clones without clinical evidence for a hematologic neoplasm. The prevalence …
PURPOSE OF REVIEW: Clonal hematopoiesis (CH) is characterized by the acquisition of somatic mutations and subsequent expansion of mutated he …
Rare Germline ATM Variants Influence the Development of Chronic Lymphocytic Leukemia.
Lampson BL, Gupta A, Tyekucheva S, Mashima K, Petráčková A, Wang Z, Wojciechowska N, Shaughnessy CJ, Baker PO, Fernandes SM, Shupe S, Machado JH, Fardoun R, Kim AS, Brown JR. Lampson BL, et al. J Clin Oncol. 2023 Feb 10;41(5):1116-1128. doi: 10.1200/JCO.22.00269. Epub 2022 Oct 31. J Clin Oncol. 2023. PMID: 36315919 Free PMC article.
We aimed to determine if rare germline ATM variants are more frequent in chronic lymphocytic leukemia (CLL) compared with other hematologic malignancies and if they influence the clinical characteristics of CLL. METHODS: We identified 3,128 patients (including 825 patients …
We aimed to determine if rare germline ATM variants are more frequent in chronic lymphocytic leukemia (CLL) compared with other hematologic …
The new tool "KIT" in advanced systemic mastocytosis.
Shomali W, Gotlib J. Shomali W, et al. Hematology Am Soc Hematol Educ Program. 2018 Nov 30;2018(1):127-136. doi: 10.1182/asheducation-2018.1.127. Hematology Am Soc Hematol Educ Program. 2018. PMID: 30504301 Free PMC article. Review.
Although mediator symptoms related to mast cell activation can impose a symptom burden in cutaneous disease and across the spectrum of systemic mastocytosis subtypes, the presence of an associated hematologic neoplasm and/or organ damage denotes advanced disease and …
Although mediator symptoms related to mast cell activation can impose a symptom burden in cutaneous disease and across the spectrum of syste …
The Role of Salvage Second Autologous Hematopoietic Cell Transplantation in Relapsed Multiple Myeloma.
Hagen PA, Stiff P. Hagen PA, et al. Biol Blood Marrow Transplant. 2019 Mar;25(3):e98-e107. doi: 10.1016/j.bbmt.2018.12.002. Epub 2018 Dec 8. Biol Blood Marrow Transplant. 2019. PMID: 30537552 Free article. Review.
Practice patterns vary significantly across institutions, and most of the literature available to guide clinical decisions consists of single-institution experiences, with only 1 randomized study evaluating the role of SAT compared with a nontransplantation approach …
Practice patterns vary significantly across institutions, and most of the literature available to guide clinical decisions consists o …
46 results